Selecta Biosciences Inc. (SELB) and China Biologic Products Holdings Inc. (NASDAQ:CBPO) Contrasting side by side

Selecta Biosciences Inc. (NASDAQ:SELB) and China Biologic Products Holdings Inc. (NASDAQ:CBPO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Selecta Biosciences Inc. N/A 5421.40 70.23M -3.14 0.00
China Biologic Products Holdings Inc. 466.88M 7.30 124.98M 3.12 25.87

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Selecta Biosciences Inc. and China Biologic Products Holdings Inc.

Profitability

Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Selecta Biosciences Inc. 0.00% -220.1% -86.5%
China Biologic Products Holdings Inc. 26.77% 6.1% 4.9%

Liquidity

1.6 and 1.6 are the respective Current Ratio and a Quick Ratio of Selecta Biosciences Inc. Its rival China Biologic Products Holdings Inc.’s Current and Quick Ratios are 10.7 and 8.9 respectively. China Biologic Products Holdings Inc. has a better chance of clearing its pay short and long-term debts than Selecta Biosciences Inc.

Analyst Ratings

Selecta Biosciences Inc. and China Biologic Products Holdings Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Selecta Biosciences Inc. 0 0 0 0.00
China Biologic Products Holdings Inc. 0 2 0 2.00

China Biologic Products Holdings Inc. on the other hand boasts of a $86 consensus price target and a -0.62% potential downside.

Institutional & Insider Ownership

Institutional investors held 53.3% of Selecta Biosciences Inc. shares and 47.4% of China Biologic Products Holdings Inc. shares. Insiders held 0.2% of Selecta Biosciences Inc. shares. Competitively, China Biologic Products Holdings Inc. has 43.13% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Selecta Biosciences Inc. -8.64% 28.03% -66.39% -84.51% -78.5% -24.44%
China Biologic Products Holdings Inc. -0.95% -0.62% 4.75% -9.74% 10.52% 6.3%

For the past year Selecta Biosciences Inc. has -24.44% weaker performance while China Biologic Products Holdings Inc. has 6.3% stronger performance.

Summary

On 10 of the 11 factors China Biologic Products Holdings Inc. beats Selecta Biosciences Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its lead product candidate is SEL-212, which is in phase I/II clinical trials for the treatment of refractory and chronic tophaceous gout. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.